🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

875 results for “A.” Clear

  1. LANSOPRAZOLE, LANSOPRAZOLE, Placebo to match lansoprazole high dose, Linaprazan glurate, Placebo to match Lansoprazole low dose, Placebo to match Linaprazan Glurate

    Pharma Mar S.A.

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  2. LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CYTARABINE, METHOTREXATE, CYTARABINE, PREDNISONE, METHOTREXATE, Melphalan 50 mg powder and solvent for solution for injection/infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, Idarubicina Sandoz 1 mg/ml concentrato per soluzione per infusione, METHOTREXATE, PREDNISONE, FILGRASTIM, Glivec 100 mg hard capsules, CYTARABINE, PURINETHOL 50 mg compresse, Dexamethasone Phosphate 4 mg/ml Solution for Injection, Keppra 250 mg film-coated tablets, ME

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    phase 3 small molecule active

    1 trial

  3. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  4. LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Pharma Mar S.A.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

    Pharma Mar S.A.

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  6. LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE

    Pharma Mar S.A.

    Glioblastoma

    phase 3 small molecule active

    1 trial

  7. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Pharma Mar S.A.

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  8. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Pharma Mar S.A.

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  9. Lecanemab

    Eisai GmbH

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial

  10. Locally sourced sterile 0.9% (w/v) sodium chloride, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  11. Lucerastat

    Pharma Mar S.A.

    Fabry disease

    phase 3 small molecule active

    1 trial

  12. MEPOLIZUMAB

    GlaxoSmithKline Biologicals S.A.

    Hypereosinophilic syndrome (HES)

    phase 3 small molecule active

    1 trial

  13. METHOTREXATE, DEXAMETHASONE, DEXAMETHASONE, CYTARABINE, CYTARABINE, DASATINIB, PREDNISOLONE, CYTARABINE, PONATINIB, CYTARABINE, METHOTREXATE, METHOTREXATE, VINCRISTINE SULFATE, PREDNISOLONE, IMATINIB MESILATE, METHOTREXATE, DEXAMETHASONE, Olverembatinib, DEXAMETHASONE, VINCRISTINE SULFATE, DEXAMETHASONE, DASATINIB, DEXAMETHASONE

    Pharma Mar S.A.

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  14. MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL

    Pharma Mar S.A.

    General anaesthesia

    phase 3 small molecule active

    1 trial

  15. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Pharma Mar S.A.

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  16. MITAPIVAT, MITAPIVAT, Placebo for AG-348, MITAPIVAT, MITAPIVAT

    Pharma Mar S.A.

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  17. MITAPIVAT, Placebo for MITAPIVAT, MITAPIVAT, MITAPIVAT, MITAPIVAT

    Pharma Mar S.A.

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  18. MITAPIVAT, Placebo for Mitapivat

    Pharma Mar S.A.

    Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  19. MT-7117 Formulation Code C

    Pharma Mar S.A.

    Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

    phase 3 small molecule active

    1 trial

  20. MT-7117 Formulation Code C, MT-7117 Placebo

    Pharma Mar S.A.

    Erythropoietic Protoporphyria or X-Linked Protoporphyria

    phase 3 small molecule active

    1 trial

  21. MaaT013

    Pharma Mar S.A.

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

  22. MomeGalen 1 mg/g cutaneous emulsion, Placebo to 0.1% mometasone furoate cutaneous emulsion (active ingredient-free vehicle of mometasone cutaneous emulsion), ECURAL Fettcreme, 1 mg/g Creme

    Pharma Mar S.A.

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  23. Mometasonfuroaat Teva 50 microgram/verstuiving, neusspray, suspensie, Mometasonfuroat-ratiopharm® 50 Mikrogramm/Sprühstoß Nasenspray, Suspension, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Severe CRSwNP patients with asthma.

    phase 3 small molecule active

    1 trial

  24. Monofer, injektions- og infusionsvæske, opløsning

    Pharma Mar S.A.

    Chronic Heart Failure

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources